Vitenskapelig artikkel

• Tilde Harridsleff Rasmussen; Stine Schikora-Rustad; Åslaug Rudjord Lorentzen et al. (2026). Low risk of severe COVID-19 in vaccinated people with multiple sclerosis: a nationwide Norwegian study. (ekstern lenke)
• Hilde Norborg; Jan Harald Aarseth; Janne Mannseth et al. (2025). Effect of early highly effective treatment compared to an escalating treatment strategy in multiple sclerosis. (ekstern lenke)
• Max Korbmacher; Ingrid Anne Lie; Kristin Wesnes et al. (2025). Multimodal predictors of disability progression and processing speed decline in relapsing–remitting multiple sclerosis. (ekstern lenke)
• Ragnhild Reehorst Lereim; Eystein Oveland; Y. Xiao et al. (2016). The Brain Proteome of the Ubiquitin Ligase Peli1 Knock-Out Mouse during Experimental Autoimmune Encephalomyelitis. (ekstern lenke)
• Helmut Butzkueven; Jan Hillert; Merja Soilu-Hänninen et al. (2023). The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis. (ekstern lenke)
• Kristin Ingeleiv Løken; Kjell-Morten Myhr; Jacob Bakke et al. (2013). Retinol levels are associated with magnetic resonance imaging outcomes in multiple sclerosis. (ekstern lenke)
• Ola Nakken; Jan Harald Aarseth; Stig Wergeland et al. (2024). BCG vaccination and multiple sclerosis risk: A Norwegian cohort study. (ekstern lenke)
• Torbjørn Kråkenes; Stig Wergeland; Niyaz Abdulbaqi Abdulmajid Al-Sharabi et al. (2023). The neuroprotective potential of mesenchymal stem cells from bone marrow and human exfoliated deciduous teeth in a murine model of demyelination. (ekstern lenke)
• Karine Eid; Øivind Torkildsen; Jan Harald Aarseth et al. (2024). Migraine in the multiple sclerosis prodrome: a prospective nationwide cohort study in pregnant women. (ekstern lenke)
• Silje Agnethe Stokke; Kjell-Morten Myhr; Trygve Holmøy et al. (2015). Body mass index influence interferon-beta treatment response in multiple sclerosis. (ekstern lenke)
• Kristin Wesnes; Kjell-Morten Myhr; Trond Riise et al. (2021). Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis. (ekstern lenke)
• Karine Eid; Øivind Fredvik Grytten Torkildsen; Jan Harald Aarseth et al. (2021). Perinatal Depression and Anxiety in Women with Multiple Sclerosis: A Population-Based Cohort Study. (ekstern lenke)
• Silje Agnethe Stokke; Kjell-Morten Myhr; Trygve Holmøy et al. (2018). Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis. (ekstern lenke)
• Kristin Nielsen Varhaug; Christian Barro; Kjetil Lauvland Bjørnevik et al. (2017). Neurofilament light chain predicts disease activity in relapsing-remitting MS. (ekstern lenke)
• Stig Wergeland; Øivind Torkildsen; Kjell-Morten Myhr et al. (2012). The cuprizone model: regional heterogeneity of pathology. (ekstern lenke)
• Agnes Elisabeth Nystad; Øivind Torkildsen; Stig Wergeland (2018). Effects of vitamin D on axonal damage during de- and remyelination in the cuprizone model. (ekstern lenke)
• Trygve Holmøy; Qin Ying Esbensen; Øivind Torkildsen et al. (2016). WT1 and interferon-β–vitamin D association in MS: a longitudinal study.. (ekstern lenke)
• Egil Rørvik Røsjø; Kjell-Morten Myhr; Kristin Ingeleiv Løken-Amsrud et al. (2015). Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis. (ekstern lenke)
• Sveinung Fjær; Lars Bø; Kjell-Morten Myhr et al. (2015). Magnetization transfer ratio does not correlate to myelin content in the brain in the MOG-EAE mouse model. (ekstern lenke)
• Karine Eid; Øivind Torkildsen; Jan Harald Aarseth et al. (2022). Association of adverse childhood experiences with the development of multiple sclerosis. (ekstern lenke)
• Marton König; Åslaug Rudjord Lorentzen; Hilde Marie Torgauten et al. (2021). Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. (ekstern lenke)
• Agnes Elisabeth Nystad; Stig Wergeland; Lage Aksnes et al. (2014). Effect of high-dose 1.25 dihydroxyvitamin D3 on remyelination in the cuprizone model. (ekstern lenke)
• Øivind Torkildsen; Kjell-Morten Myhr; Stig Wergeland (2014). Treatment-resistant immune thrombocytopenic purpura associated with LDN use in a patient with MS. (ekstern lenke)
• Karine Eid; Øivind Torkildsen; Jan Harald Aarseth et al. (2022). Abuse and revictimization in adulthood in multiple sclerosis: a cross-sectional study during pregnancy. (ekstern lenke)
• Stig Wergeland; Anagha P Parkar; Snezana Maric et al. (2021). En ung kvinne med langvarig kvalme, oppkast og hikke. (ekstern lenke)
• Eystein Oveland; Agnes Elisabeth Nystad; Frode Berven et al. (2017). 1,25-Dihydroxyvitamin-D3 induces brain proteomic changes in cuprizone mice during remyelination involving calcium proteins. (ekstern lenke)
• Andrea Kyvik Habbestad; Johannes Sverre Willumsen; Jan Harald Aarseth et al. (2023). Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study. (ekstern lenke)
• Øivind Torkildsen; Kristin Ingeleiv Løken-Amsrud; Stig Wergeland et al. (2013). Fat-soluble vitamins as disease modulators in multiple sclerosis. (ekstern lenke)
• Hilde Marie Torgauten; Therese Bredholt Onyango; Sonja Ljostveit et al. (2024). Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients. (ekstern lenke)
• Kjetil Lauvland Bjørnevik; Kjell-Morten Myhr; Antonie Giæver Beiske et al. (2018). α-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients.. (ekstern lenke)
• Maria Nordheim Alme; Agnes Elisabeth Nystad; Lars Bø et al. (2015). Fingolimod does not enhance cerebellar remyelination in the cuprizone model. (ekstern lenke)
• Øivind Torkildsen; Stig Wergeland; Jacob Bakke et al. (2012). ω-3 fatty acid treatment in multiple sclerosis (OFAMS study): a randomised, double blind, placebo-controlled trial. (ekstern lenke)
• Agnes Elisabeth Nystad; Ragnhild Reehorst Lereim; Stig Wergeland et al. (2019). Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model. (ekstern lenke)
• Stig Wergeland; Øivind Torkildsen; Kjell-Morten Myhr et al. (2011). Dietary vitamin D3 supplements reduce demyelination in the cuprizone model. (ekstern lenke)
• Brit Ellen Rød; Stig Wergeland; Kjetil Lauvland Bjørnevik et al. (2023). Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy. (ekstern lenke)
• Hilde Marie Torgauten; Kjell-Morten Myhr; Stig Wergeland et al. (2021). Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study. (ekstern lenke)
• Jens Kuhle; G Disanto; R Dobson et al. (2015). Conversion from clinically isolated syndrome to multiple sclerosis: A large multicantre study. (ekstern lenke)
• Jan Hillert; Helmut Butzkueven; Melinda Magyari et al. (2024). Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study. (ekstern lenke)
• Sveinung Fjær; Lars Bø; Arvid Lundervold et al. (2013). Deep gray matter demyelination detected by magnetization transfer ratio in the cuprizone model. (ekstern lenke)
• Kristin Ingeleiv Løken-Amsrud; Kjell-Morten Myhr; Søren Jacob Bakke et al. (2013). Alpha-tocopherol and MRI outcomes in multiple sclerosis - association and prediction. (ekstern lenke)
• Kerstin Hellwig; Melinda Magyari; Thomas M. MacDonald et al. (2025). A multi-country cohort database study to assess pregnancy and infant outcomes after potential maternal or paternal exposure to cladribine tablets in the treatment of multiple sclerosis: the CLEAR study methods and status update. (ekstern lenke)
• Silje Kvistad; Kjell-Morten Myhr; Trygve Holmøy et al. (2016). No association of tobacco use and disease activity in multiple sclerosis. (ekstern lenke)
• Intakhar Ahmad; Stig Wergeland; Eystein Oveland et al. (2023). An Association of Chitinase-3 Like-Protein-1 With Neuronal Deterioration in Multiple Sclerosis. (ekstern lenke)
• Stig Wergeland; Kjell-Morten Myhr; Kristin Ingeleiv Løken-Amsrud et al. (2016). Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients. (ekstern lenke)
• Brit Ellen Rød; Einar August Høgestøl; Øivind Torkildsen et al. (2025). Comparative effectiveness of rituximab and cladribine in relapsing–remitting multiple sclerosis: A target trial emulation. (ekstern lenke)
• Trygve Holmøy; Kristin Ingeleiv Løken-Amsrud; Jacob Bakke et al. (2013). Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activity. (ekstern lenke)
• Maria Therese Fossum; Hilde Marie Torgauten; Jan Harald Aarseth et al. (2025). Early extended interval dosing of rituximab in multiple sclerosis: A comparative cohort study on efficacy and safety. (ekstern lenke)
• Egil Rørvik Røsjø; Kjell-Morten Myhr; Kristin Ingeleiv Løken-Amsrud et al. (2014). Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis. (ekstern lenke)
• Hilde Norborg; Trond Riise; Kjell-Morten Myhr et al. (2021). Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis. (ekstern lenke)
• Malte Roar; Amalie Rhode Høgh Nielsen; Jonas Munksgaard Berg et al. (2023). Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study. (ekstern lenke)
• Brit Ellen Rød; Øivind Torkildsen; Kjell-Morten Myhr et al. (2022). Safety of breast feeding during rituximab treatment in multiple sclerosis. (ekstern lenke)
• Eystein Oveland; Intakhar Ahmad; Ragnhild Reehorst Lereim et al. (2021). Cuprizone and EAE mouse frontal cortex proteomics revealed proteins altered in multiple sclerosis. (ekstern lenke)
• Jakob Rishovd Karlowicz; Mattias Klakegg; Jan Harald Aarseth et al. (2023). Predictors of hospitalization due to infection in rituximab-treated MS patients. (ekstern lenke)
• Ingrid Anne Lie; Kristin Wesnes; Silje Agnethe Stokke Kvistad et al. (2022). The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis. (ekstern lenke)
• Intakhar Ahmad; Stig Wergeland; Eystein Oveland et al. (2021). A higher proportion of ermin-immunopositive oligodendrocytes in areas of remyelination. (ekstern lenke)
• Kjell-Morten Myhr; Nina Agnethe Grytten; Øivind Torkildsen et al. (2012). A need for national registries and international collaborative research in multiple sclerosis. (ekstern lenke)
• Ingrid Anne Lie; Sezgi Kacar; Kristin Wesnes et al. (2022). Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study. (ekstern lenke)
• Kristin Ingeleiv Løken-Amsrud; Trygve Holmøy; Søren J. Bakke et al. (2012). Vitamin D and disease activity in multiple sclerosis before and during interferon beta treatment. (ekstern lenke)
• Silje Agnethe Stokke; Kjell-Morten Myhr; Trygve Holmøy et al. (2014). Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis. (ekstern lenke)

Konferanseabstrakt

• Tori Smedal; Kyrre Breivik; Roshan das Nair et al. (2025). Evaluating the response categories of the Multiple Sclerosis Impact Scale-29: A Rasch Analysis. (ekstern lenke)
• SS Kvistad; Kjell-Morten Myhr; Trygve Holmøy et al. (2013). Antibodies to Epstein-Barr virus and disease activity in multiple sclerosis. (ekstern lenke)
• Jens Kuhle; R Dobson; JP Bestwick et al. (2013). Multivariate clinically isolated syndrome (CIS) risk factor study: towards individual prognosis and treatment indication in CIS. (ekstern lenke)
• Stig Wergeland; Øivind Fredvik Torkildsen; Kjell-Morten Myhr et al. (2009). Histopathological characterisation of the cuprizone model for demyelination. (ekstern lenke)
• Øivind Torkildsen; Kjell-Morten Myhr; Antonie Giæver Beiske et al. (2017). alpha-Linolenic acid (ALA) serum levels are associated with reduced MRI activity in a prospective cohort of MS patients. (ekstern lenke)

Fagartikkel

• Einar August Høgestøl; Piotr Sowa; Trygve Holmøy et al. (2025). Oppdaterte diagnosekriterier for multippel sklerose. (ekstern lenke)

Konferanseposter

• Linn Elin Rødal; Tori Smedal; Stig Wergeland et al. (2025). Tidlig screening av blæredysfunksjon ved multippel sklerose - et kvalitetsforbedringsprosjekt. (ekstern lenke)
• Marton König; Åslaug Rudjord Lorentzen; Hilde Marie Torgauten et al. (2021). Humoral Immunity to SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis using High-Efficacy Disease Modifying Therapies. (ekstern lenke)
• Sveinung Fjær; Stig Wergeland; Lars Bø (2014). Magnetization transfer ratio (MTR) increased unexpectedly in EAE induced mice.. (ekstern lenke)
• Tilde Rasmussen; Marton König; Åslaug Rudjord Lorentzen et al. (2022). Safety of a third SARS CoV 2 mRNA vaccine dose in people with multiple sclerosis. (ekstern lenke)
• Marton König; Asia-Sophia Fumika Michaela Wolf; Anthony Ravussin et al. (2022). Immunogenicity and efficacy of mRNA-COVID-19 vaccines in people with multiple sclerosis. (ekstern lenke)

Vitenskapelig litteraturgjennomgang

• Stig Wergeland; Øivind Torkildsen; Lars Bø et al. (2012). Polyunsaturated fatty acids in multiple sclerosis therapy. (ekstern lenke)
• Kjell-Morten Myhr; Nina Grytten; Øivind Torkildsen et al. (2015). The Norwegian Multiple Sclerosis Registry and Biobank. (ekstern lenke)
• Silje Agnethe Stokke; Stig Wergeland; Øivind Torkildsen et al. (2013). Neuromyelitis optica. (ekstern lenke)

Doktorgradsavhandling

• Stig Wergeland (2013). Vitamin D and ω-3 polyunsaturated fatty acids as disease modifying factors in multiple sclerosis. (ekstern lenke)

Fremhevet artikkel i media

• Øivind Torkildsen; Brit Ellen Rød; Lars Bø et al. (2022). Amming og behandling av multippel sklerose. (ekstern lenke)

Leserbrev

• Stig Wergeland; Trond Riise; Øivind Torkildsen (2018). Response to 'Seasonal variation of vitamin D and Epstein?Barr virus antibody in multiple sclerosis patients', a comment letter regarding 'Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients'. (ekstern lenke)
• Ingrid Anne Lie; Brit Ellen Rød; Silje Agnethe Stokke et al. (2023). Interferon β1a treatment does not influence serum Epstein-Barr virus antibodies in patients with multiple sclerosis. (ekstern lenke)

Konferanseforedrag

• Egil Rørvik Røsjø; Kjell-Morten Myhr; Margitta Theodora Kampman et al. (2015). Vitamin D og interferon-behandling ved multippel sklerose. (ekstern lenke)

Se en fullstendig oversikt over publikasjoner i NVA.